You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Novo Nordisk Articles
Popular Novo Nordisk Articles
Highly Recommended Novo Nordisk Articles
Send a link to this page to your friends and colleagues.
Novo Nordisk Pharmaceuticals has introduced a new oral antidiabetic agent called Prandin (repaglinide). The medication is intended for people with type 2 diabetes, who are unable to satisfactorily control their hyperglycemia through diet and exercise. It can also be used in combination with metformin, which works with Prandin to control blood sugars.
Prandin stimulates the beta cells in the pancreas to secrete more insulin. It is taken orally as a tablet at mealtimes and works quickly and for a very short period of time. This helps patients manage their glucose load during meals, a key factor in the control of type 2 diabetes.
Although Prandin shows promise, it is not for everyone. Wendell Cheatham, MD, medical director of Novo Nordisk Pharmaceuticals, Inc., explains, "For many individuals with type 2 diabetes, insulin is still the appropriate therapy." He also notes that Prandin is not intended for type 1 patients, as it cannot restore their beta cell function.
Prandin does interact with some drugs that treat fungal and bacterial infections and troglitazone (a diabetes pill). Prandin may also cause low-glucose reactions, particularly if used with other drugs that lower glucose levels. Studies are currently underway to evaluate use of Prandin in combination with other drugs.
0 comments - Jul 1, 1998
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.